Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of Nicotine-Qbeta Vaccine in Smokers
NCT00369616Phase 2Completed
- Sponsor
- Cytos Biotechnology AG
- Start
- Dec 2003
- Primary completion
- Mar 2005
- Modality
- Therapeutic Vaccines, Recombinant Protein Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of NIC002 in nicotine dependence, sponsored by Cytos Biotechnology AG. Started Dec 2003; status: completed.
02
Drugs
NIC002
03
Conditions
nicotine dependence
Beyond the preview
Go deeper on NCT00369616.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00369616.